Key result
The succinate receptor SUCRN1 and its ligand act as detectors of local stress in the kidney, potentially playing a key role in hypertension and metabolic diseases.
Answers are grounded in this paper and cite their sources.
The succinate receptor SUCRN1 is identified as a potential therapeutic target for hypertension and metabolic diseases due to its role in detecting local stress and activating the renin-angiotensin system.
The G protein-coupled succinate and α-ketoglutarate receptors are closely related to the family of P2Y purinoreceptors. Although the α-ketoglutarate receptor is almost exclusively expressed in the kidney, its function is unknown. In contrast, the succinate receptor, SUCRN1, is expressed in a variety of tissues, including blood cells, adipose tissue, liver, retina, and the kidney. Recent evidence suggests SUCRN1 and its succinate ligand are novel detectors of local stress, including ischemia, hypoxia, toxicity, and hyperglycemia. Local levels of succinate in the kidney also activate the renin-angiotensin system and together with SUCRN1 may play a key role in the development of hypertension and the complications of diabetes mellitus, metabolic disease, and liver damage. This makes the succinate receptor a promising drug target to counteract an expanding number of interrelated disorders.
No takes yet. Share an insight, caveat, or question.
Deen et al. (2011) conducted a review in hypertension and metabolic diseases. Succinate receptor (SUCRN1) was evaluated. The succinate receptor SUCRN1 and its ligand act as detectors of local stress in the kidney, potentially playing a key role in hypertension and metabolic diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: